AbbVie Inc.
ABBV · NYSE
ABBV · NYSE
AbbVie has a Buy consensus from 22 analysts, with targets ranging from $265 to $300, a $280 mean and a $35 spread between the low and high. The supplied evidence does not identify the named firm with the highest $300 target or the firm at the $265 low, so it cannot establish who is most or least bullish. It also provides no attributable rating or target revisions during the past week. The substantive disagreement is valuation versus growth durability: bullish analysts appear to credit AbbVie's earnings, dividend and product opportunities, while bearish valuation commentary focuses on the stock's premium and dependence on Skyrizi. Other published target aggregators show materially different samples and ranges, underscoring dispersion.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Barclays PLC | — | $300 | +14.6% | Jul 29, 2026 | Open the report this row came from | |
| Barclays PLC | — | $300 | +14.6% | Jul 29, 2026 |
| Open the report this row came from |
| Wolfe Research | — | — | — | Jan 8, 2026 | Open the report this row came from |
| HSBC | — | $265 | +1.2% | Dec 10, 2025 | Open the report this row came from |
| HSBC | — | $265 | +1.2% | Dec 10, 2025 | Open the report this row came from |
